# A Study of MRG003 in Patients With Advanced Solid Tumors

> **NCT04868344** · PHASE1 · COMPLETED · sponsor: **Shanghai Miracogen Inc.** · enrollment: 61 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** MRG003

## Key facts

- **NCT ID:** NCT04868344
- **Lead sponsor:** Shanghai Miracogen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-09
- **Primary completion:** 2021-03-29
- **Final completion:** 2021-03-29
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2021-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04868344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04868344, "A Study of MRG003 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04868344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*